AEO for biotech
A licensing scout describes an indication and a stage to an answer engine and reads one paragraph. Five public records decide whether your asset is in it, and you control one of them.
The short answer
It is not content marketing with a new acronym. Most of the work in this industry happens off your own domain, in registries and databases you may never have logged into, because that is where an engine goes when your own pages do not answer the question.
Three ways the same company gets asked about
The same engine, the same day, behaves very differently depending on which of these a person types. The difference is not knowledge. It is retrieval.
| How they ask | Who asks it that way | What usually happens |
|---|---|---|
| By name — “What is Company working on?” | Someone who already heard of you: an analyst, a recruit, a partner doing a second pass. | Fluent and usually accurate. Your own site is often cited. This is the question that makes a team think visibility is fine. |
| By problem — “Who has a preclinical asset for indication?” | A business development or licensing scout who has not heard of you. The one that matters. | A list of companies assembled from third-party sources. You are in it or you are not, and nothing about your own site decides that on its own. |
| By code — “What is ABC-1234, and who owns it?” | A scout who found an asset code in a database or a conference abstract and is tracing it back. | The hardest one. If the code exists only in a third-party row and nowhere on your domain, an engine can fail to connect it to you at all. |
The gap between the first row and the other two is the whole diagnosis. A company can be described perfectly when named and be absent from every answer where it was not. Those are different retrieval paths, and only the first one is flattering.
What the engine is reading
Whoever can reach the records the answer is actually built from. For a drug developer that is five of them, and only one is your own website — which is why this is not a website project.
| Record | What it settles | How it goes wrong |
|---|---|---|
| Your own site | What you say you are, in your own words. The only source you control outright. | A pipeline page that lists disease areas with no asset names, no stage in the page text and a date stamp from last year. An engine cannot cite a contact form. |
| Trial registries | Sponsor, phase, indication, status. High authority, machine-readable, widely mirrored. | Sponsor name spelled differently from your legal name, so the entry never joins up with the rest of the record. |
| Third-party pipeline databases | Asset codes, targets, stages — often the only place your assets are listed by name. | They use their own indication vocabulary and their own naming. If your site never corroborates it, their version is the only version. |
| Wire releases and trade press | Partnerships, financings, programme starts, with a date and a quote. | Excellent for the eighteen months after publication, then quietly stale. The record says what you were doing, not what you are doing. |
| Publications and abstracts | Mechanism, data, credibility with a technical reader. | Author affiliations and compound codes often do not match the company-facing names, so the science and the company sit in separate records. |
The order to fix it in
These are the patterns we look for first in a diagnostic, in the order they tend to cost a mention. Fixing the fourth before the first is a common and expensive mistake.
If the pipeline page says the asset list is being updated and invites an email, every question about what you have available is answered from somewhere else. An engine cannot cite an email address. This is the single most common finding and the cheapest to fix.
Codes appear in a third-party database with no corroboration on your own site. Nothing anchors them to you, so a question that starts from the code may not reach you — and when two or three naming conventions are in circulation, none of them accumulates authority.
Your site says one thing and the registry or database says the clinical synonym. A scout searching either phrasing matches only one of the two records, and the engine has no reason to believe they describe the same programme.
A graphic with hit, lead, candidate and preclinical columns is a picture. If the marker is not in the page text, the field a business development screen filters on first cannot be extracted at all.
Underneath all four is usually one thing: a page meant to show current state, last updated a long time ago. An engine has no way to know it is stale, so it reads it as true or ignores it in favour of something that looks fresher.
What we will not do
No hidden text, no instructions addressed to an AI inside a page, no serving crawlers something different from readers. If it only works because a model read it and a person did not, we do not ship it.
No fabricated reviews, no testimonials from people who do not exist, no byline on a person who did not write it. The whole method depends on the record being true, and a planted source is the fastest way to poison it.
Every sentence we publish about you links to a fact you approved or a public page we can cite. Nothing goes out, anywhere, without your written approval on the specific thing going out.
Questions
It is the case it works best in. A company with nothing on the market is described almost entirely by records it does not own — a trial registry, a third-party pipeline database, a press release from two years ago. Those are exactly the sources an answer engine reaches for, and exactly the ones nobody at the company is reading.
Because the database answers the question and the site does not. A pipeline page that lists disease areas without asset names, stages or dates gives an engine nothing it can lift, so it sources the answer elsewhere and inherits whatever that elsewhere says — including the naming conventions and indication wording you did not choose.
PR aims at a person reading a publication. This aims at the record that is left behind once the news cycle ends. A wire release does help, because engines read the wires, but it decays; a registry entry, a database row and a page that states a stage in plain text keep answering the question a year later.
Business development feels it first, because a partner conversation starts with a scout describing a problem to an engine. Investor relations and recruiting feel the same effect with different questions. It is usually nobody's job, which is why the records drift.
Related reading
The commercial case for a marketing lead with two people and a conference budget.
The asset-level version of this page: the records a licensing scout’s engine reads, and what it takes to be in the list.
The industry-neutral definition, how an engine decides whose name goes in, and the five things that move it.
The page-level mechanics: what makes a sentence liftable, and what does not work.
The holdout method, which is how you tell a real improvement from a market that moved.
Start here
The free diagnostic: how public sources describe your company and your main product today, where they disagree, and which disagreement to fix first. Every line links to the page we read it from. Nothing is published anywhere without your written approval.